Xinhua News Agency, Jerusalem, September 24 (Reporter Lv Yingxu Shanghao) Israeli media recently reported that according to the instructions of the Israeli Ministry of Health, some patients infected with the new crown virus in the country can receive "antibody cocktail therapy" from the 23rd, and use the therapy. Included in medical insurance coverage.

  According to Israel’s Haaretz, the Israeli Ministry of Health has recently purchased thousands of doses of "antibody cocktail therapy" from the American Regeneron Pharmaceuticals, at a cost of approximately US$1,500 per COVID-19 patient.

  According to relevant regulations, this therapy is suitable for high-risk groups among Israeli patients with mild to moderate symptoms of new coronary disease, including chronic diabetes, kidney disease, liver disease, cardiovascular disease, and immunodeficiency patients with mild to moderate new coronary disease. This part of the population does not Obvious respiratory symptoms, but the risk of turning to severe illness or even death is very high.

  Israeli patients with mild to moderate COVID-19 are usually treated at home.

Patients cannot apply for the therapy on their own, and the staff of Israeli medical insurance institutions will contact eligible patients and proceed with the treatment with the patient's consent.

The first batch of 17 patients received the treatment on the 23rd through two medical insurance institutions, Maccabee Health Care Services Company and Clarit Health Services Society.

  Regeneron Pharmaceuticals' "antibody cocktail therapy" REGEN-COV contains two monoclonal antibodies designed to block the process of new coronavirus infecting the human body.

The combined use of the two antibodies can reduce the ability of mutant new coronavirus strains to evade single antibody treatment.

According to a report in Haaretz, the results of the test of Regeneron Pharmaceuticals on the treatment show that using the treatment within 72 hours after the onset of symptoms of new crown infection, the effective rate of preventing patients from becoming severely ill is 70%.

Keywords: